Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.

Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.

Abstract: The device for assisting determination of pathology of a polycystic kidney disease according to the present invention has an extraction means 21 for extracting gene mutation information in a region related to polycystic kidney disease using sequence data showing gene sequences of a test subject; an acquisition means 22 for acquiring, using the extracted gene mutation information, medical information corresponding to the extracted gene mutation from a plurality of databases in which gene mutation and medical information are associated with each other; and a list display means 23 for displaying a list containing the extracted gene mutation information and the obtained medical information.

Abstract: A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound.

Abstract: A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound.

Abstract: A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound.

Abstract: The invention relates to a method of diagnosing a risk of a thermolabile phenotype disease including or caused by influenza encephalitis/encephalopathy, Reye's syndrome, RS virus infectious disease, adenovirus infectious disease, rhinovirus infectious diseases, bastard measles, Japanese encephalitis, malaria infectious disease, Kawasaki disease and sudden infant death syndrome, characterized by examining whether or not an enzymatic activity of at least one enzyme involved in any of various transporters, carnitine cycle, long-chain ? oxidation cycle, medium-chain/short-chain ? oxidation cycle, electron transfer, synthesis of a ketone and production of ATP involved in energy metabolism in mitochondria is significantly lower compared with healthy subjects at 39° C. or higher when referring the enzymatic activity at 37° C. as to 100%.

Abstract: The present invention provides an effective method for detecting hepatocellular carcinoma in a tested tissue, which comprises the step of measuring the expression level(s), in the tested tissue, of at least one gene selected from the group consisting of plasminogen gene, EST51549, retinol-binding protein 4 gene and organic anion transporter C gene, and a method comprising the step of measuring, in the tested tissue, the expression level(s) of at least one gene selected from the group consisting of plasminogen gene, EST51549, retinol-binding protein 4 gene and organic anion transporter C gene, and, in the tested tissue, at least one gene selected from the group consisting of aldolase B gene, carbamyl phosphate synthase 1 gene, albumin gene and cytochrome P450 subfamily 2E1 gene.

Abstract: The present invention provides a method for detecting polymorphism of the human cytochrome P4501A2 (CYP1A2) gene in which substitution at a 2064th base, substitution at a 2640th base, and/or deletion of a -1569th base in a nontranslational region of the human cytochrome P4501A2 gene are/is detected. According to the method of the invention, new types of polymorphism of the CYP1A2 gene can be detected simply and easily with high sensitivity and accuracy, and the method requires only a small amount of a DNA sample.

Abstract: The invention provides polymorphic human arylamine N-acetyltransferase (NAT) genes, more precisely a type 1 NAT gene containing the 5'-noncoding region base sequence of SEQ ID NO:1 and the coding region-containing base sequence of SEQ ID NO:2, a type 2 NAT gene containing the sequences of SEQ ID NO:3 and SEQ ID NO:4 and a type 3 NAT gene containing the sequences of SEQ ID NO:5 and SEQ ID NO:6, as well as a method of detecting these polymorphic genes and a method of diagnosing an adverse effect or effects to be caused by an amino-containing aromatic substance.